⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159675 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL22322219 | 0.97 | OPRM1 (0.31) | — | |
| SCHEMBL18996880 | 0.83 | OPRM1 (0.40) | — | |
| SCHEMBL11298108 | 0.81 | OPRM1 (0.50) | — | |
| SCHEMBL2042721 | 0.79 | OPRM1 (0.48) | — | |
| SCHEMBL28671936 | 0.79 | OPRM1 (0.48) | — | |
| SCHEMBL6122091 | 0.75 | — | — | |
| SCHEMBL2426319 | 0.75 | — | — | |
| SCHEMBL805404 | 0.75 | — | — | |
| SCHEMBL11216159 | 0.74 | OPRM1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177604-A1 | HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-14 | — | — | EP | claimed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | claimed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| CN-113874426-A | Water-soluble film and package | 株式会社可乐丽 | 2021-12-31 | — | — | CN | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| EP-2763976-B1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-105431413-A | Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC | 2016-03-23 | — | — | CN | disclosed |
| US-20150291609-A1 | MERTK-SPECIFIC PYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-10-15 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012170175-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | BAUSCH & LOMB INCORPORATED (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| EP-2049112-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | Bausch & Lomb Incorporated (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021728-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED' GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |